Navigate to Other Instruments
INCYIncyte Corporation
Incyte Corporation
INCYKey Takeaways
Last updated: 2026-09-28- •FDA approval of Atebrioz is a 'regulation_final' event — binary risk is fully removed, shifting focus to commercial execution.
- •H.C. Wainwright's price target raise post-approval signals analyst confidence in Incyte's revenue trajectory for the new drug.
- •Incyte's concurrent M&A strategy (Star Therapeutics, Vega Therapeutics) provides a multi-product pipeline that supports higher valuation multiples.
- •XBI and IBB may see marginal positive sector sentiment spillover, though INCY-specific impact dominates.
- •The Q2 guidance miss overhang may be partially offset by the Atebrioz approval, improving the medium-term risk/reward for INCY CFD longs.
Price & Market Structure
Trading Regime Status
Glossary
Key listed-stock and CFD terms, one line each — so the page is unambiguous for both readers and AI answer engines.
| Stock CFD | A contract for difference on a share price — price exposure only, not ownership of the underlying shares. |
|---|---|
| Extended hours | Pre-market and after-hours trading outside the exchange’s regular session. |
| Basis risk | The risk that the CFD reference price and the exchange execution price do not move in step. |
| P/E | Price-to-earnings ratio = share price ÷ earnings per share; a common valuation gauge. |
| Gross margin | Gross profit ÷ revenue; reflects product-level profitability. |
| EPS | Earnings per share = net income ÷ diluted shares outstanding. |
Latest Pulses
H.C. Wainwright Raises Incyte Price Target Following Atebrioz FDA Approval
H.C. Wainwright has raised its price target on Incyte Corporation (INCY) following the U.S. Food and Drug Administration's approval of Atebrioz, marking a meaningful regulatory milestone for the compa
Incyte Q2 Earnings Smash: $3.09 EPS Beats by $0.94, But Guidance Miss Creates a Two-Sided CFD Trade
Incyte Corporation (NASDAQ: INCY) reported Q2 non-GAAP EPS of $3.09, beating consensus estimates by approximately $0.94, and revenue of $1.67 billion, surpassing analyst expectations by roughly $180 m
Incyte Acquires Vega Therapeutics for $1.25B — Hematology Bet Deepens Biotech M&A Wave
Incyte Corporation (NASDAQ: INCY) has announced the acquisition of Vega Therapeutics, a privately held hematology-focused biotech developed within the Star Therapeutics company-creation platform, for
Incyte's ~$2B Star Therapeutics Deal: Leverage Scenarios & Biotech M&A Read-Through
As reported by the Financial Times, Incyte Corporation (INCY) is nearing a deal valued at approximately $2 billion to acquire Star Therapeutics, a private blood disorder drug developer. The deal has n
Get Started with Incyte Corporation
Start trading Incyte Corporation on CoinUnited.io with industry-leading leverage and fees that drop to 0% at the top VIP tier.
Trade with Leverage
Trade INCY CFDs with up to 1000x leverage on CoinUnited.io.
- Up to 1000x leverage
- Fees down to 0%
- Advanced risk management tools
Explore Stocks
Browse the full stocks market on CoinUnited.io with 125+ instruments.
- 125+ stocks instruments
- Real-time market data
- Professional charting tools
Learn Stocks Trading
Read our in-depth research and analysis on stocks markets.
- Expert market analysis
- Technical analysis basics
- Daily market insights
How to Trade Incyte Corporation: Step-by-Step Guide
Learn how to trade Incyte Corporation (INCY) on CoinUnited.io with up to 1000x leverageand volume-tiered fees that reach 0% at the top VIP level. Follow this simple step-by-step guide to start CFD trading today.
Create Your CoinUnited.io Account
Sign up at CoinUnited.io in under a minute. You'll need an email address to get started.
- ✓Quick and free registration
- ✓Email and password setup
- ✓Two-factor authentication for security
Verify Your Identity
Complete the KYC verification process to unlock full trading features and higher limits.
- ✓Upload government-issued ID
- ✓Proof of address document
- ✓Usually verified within minutes
Deposit Funds
Fund your account using one of the supported deposit methods.
Deposit Methods
- •Cryptocurrency deposits (BTC, ETH, USDT)
- •Bank transfer available
- •No minimum deposit requirement
Find INCY in the Stocks Section
Navigate to the stocks market section and search for INCY. You can trade Incyte Corporation as a CFD with up to 1000x leverage.
- ✓Search for "INCY" in the trading platform
- ✓Select CFD trading mode
- ✓Review the current price and market data
Place Your Trade
Choose your position direction (long or short), set your leverage, and enter your position size to trade Incyte Corporation.
- ✓Long (buy) if you expect INCY to rise
- ✓Short (sell) if you expect INCY to fall
- ✓Set stop-loss and take-profit levels
Monitor & Manage Risk
Keep track of your open positions and manage risk with stop-loss orders and position sizing.
- ✓Monitor P&L in real-time
- ✓Adjust stop-loss as needed
- ✓Never risk more than you can afford to lose
Order Types
Market Order
Execute immediately at the current market price. Best for quick entries.
Limit Order
Set a specific price to enter. The order fills only when the market reaches your price.
Stop-Loss Order
Automatically close your position at a specified price to limit potential losses.
Important Tips
- • Start with a small position to understand how leverage works
- • Always set a stop-loss to protect your capital
- • Higher leverage amplifies both gains and losses
- • Never invest more than you can afford to lose
Tags
Similar Stocks Assets
Explore other stocks instruments in the same sector as Incyte Corporation. Compare performance and find trading opportunities.

Jabil Inc.

Zeta Global Holdings Corp.
ProShares UltraShort Silver

TransUnion

ConAgra Brands, Inc.
Frequently Asked Questions
Incyte Corporation is a stocks instrument available for trading on CoinUnited.io.
Disclaimers & References
Important Risk Disclaimer
A CoinUnited stock CFD gives price exposure to Incyte Corporation only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.
Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.
Users should conduct their own research and consult with qualified financial professionals before making any investment decisions. The creators and operators of this platform assume no responsibility for any financial losses or other damages that may result from reliance on the information provided.
Leveraged trading is extremely risky and you may lose your entire deposit.
Methodology Overview
Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.
- Financial statements: the company's own SEC filings (10-K / 10-Q), read from XBRL
- Market data: the CoinUnited reference price and daily closes
- Institutional ownership: SEC Form 13F quarterly filings
- Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited's view
- Peer multiples: third-party trailing-twelve-month ratios
CoinUnited does not publish a price forecast or target for Incyte Corporation.
Last methodology review:
Ready to Start Trading Incyte Corporation?
Join thousands of traders and start your Incyte Corporation trading journey today. Get access to advanced trading tools and competitive fees.



